Aducanumab’s accelerated approval was controversial and insurance coverage of the expensive therapy was limited. Biogen said it is ending the ENVISION clinical study for aducanumab, a postmarketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results